Literature DB >> 32423959

Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.

Christian M Gill1, Tomefa E Asempa1, David P Nicolau2,3.   

Abstract

Animal infection models are invaluable in optimizing antimicrobial dosage in humans. Utilization of human-simulated regimens (HSRs) in animal models helps to evaluate antimicrobial efficacy at clinically achievable drug concentrations. To that end, pharmacokinetic studies in infected animals and confirmation of the HSR pharmacokinetic profile are essential in evaluating observed versus expected drug concentrations. We present and compare two murine meropenem-vaborbactam HSR profiles, their potential impact on bacterial killing, and clinical translatability.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  human-simulated exposure; murine model; pharmacodynamics; pharmacokinetics; β-lactams

Mesh：

Substances：

Year:  2020        PMID： 32423959      PMCID： PMC7526837          DOI： 10.1128/AAC.00594-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Breakpoint determination when multiple organisms are tested for effect targets.

Authors:  G L Drusano; Arnold Louie
Journal:  Eur J Pharm Sci       Date:  2019-01-31       Impact factor: 4.384

2.  Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.

Authors:  Mojgan Sabet; Ziad Tarazi; Debora Rubio-Aparicio; Thomas G Nolan; Jonathan Parkinson; Olga Lomovskaya; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.

Authors:  Kazuhiro Oshima; Shigeki Nakamura; Naoki Iwanaga; Koji Takemoto; Taiga Miyazaki; Kastunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno; Koichi Izumikawa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

7.  Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.

Authors:  H F Chambers; L Basuino; B A Diep; J Steenbergen; S Zhang; P Tattevin; J Alder
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.

Authors:  Seth T Housman; Jared L Crandon; Wright W Nichols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

9.  Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Authors:  Eric Wenzler; Mark H Gotfried; Jeffrey S Loutit; Stephanie Durso; David C Griffith; Michael N Dudley; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

Review 10.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191
View more
  2 in total

Review 1.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

2.  Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome.

Authors:  Shana R Leopold; Kamilia Abdelraouf; David P Nicolau; Hanako Agresta; Jethro Johnson; Kathleen Teter; Wm Michael Dunne; David Broadwell; Alex van Belkum; Lisa M Schechter; Erica J Sodergren; George M Weinstock
Journal:  Front Microbiol       Date:  2022-02-17       Impact factor: 5.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.